KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax: 2022-2024

Historic Long-Term Deferred Tax for Acadia Pharmaceuticals (ACAD) over the last 3 years, with Dec 2024 value amounting to $8.7 million.

  • Acadia Pharmaceuticals' Long-Term Deferred Tax rose 27.94% to $8.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.7 million, marking a year-over-year increase of 27.94%. This contributed to the annual value of $8.7 million for FY2024, which is 27.94% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Long-Term Deferred Tax stood at $8.7 million, which was up 27.94% from $6.8 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $8.7 million in FY2024 and a low of $1.2 million during FY2022.
  • Over the past 3 years, Acadia Pharmaceuticals' median Long-Term Deferred Tax value was $6.8 million (recorded in 2023), while the average stood at $5.6 million.
  • Data for Acadia Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY surged of 466.67% (in 2023) over the last 5 years.
  • Acadia Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $1.2 million in 2022, then skyrocketed by 466.67% to $6.8 million in 2023, then rose by 27.94% to $8.7 million in 2024.